AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: [14C]AZD5363 (Capivasertib)
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT05419401
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Phase 1
Recruiting
- Conditions
- Advanced Solid Malignancies
- Interventions
- Drug: [11C]AZ1419 3391Drug: Datopotamab Deruxtecan (Dato-DXd)
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 535
- Registration Number
- NCT05417594
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.
Completed
- Conditions
- Hyperkalemia
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1331
- Registration Number
- NCT05408039
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Phase 1
Terminated
- Conditions
- Urinary Bladder NeoplasmsColorectal CancerCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT05397171
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT05398263
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT05395117
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
PASS of Paediatric Patients Initiating Selumetinib
Recruiting
- Conditions
- Neurofibromatosis Type 1
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT05388370
- Locations
- 🇬🇧
Research Site, Newcastle, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 183
- Registration Number
- NCT05384262
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
FAsenra Safety Trial in India
Phase 4
Completed
- Conditions
- In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 139
- Registration Number
- NCT05384938
- Locations
- 🇮🇳
Research Site, Vishakhapatnam, India
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
Phase 2
Terminated
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 251
- Registration Number
- NCT05375760
- Locations
- 🇺🇸
Research Site, Annandale, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath